PF-06821497 (Mevrometostat)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PF-06821497 (Mevrometostat), covering 2026-04-16 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). [Phase 3]